Schizoaffective Disorder: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019–2025)

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Schizoaffective Disorder: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019–2025)

  • 192 Pages | Published On: 11-Mar-18 | Format:PDF | Last Updated: Updation in process
  • “GervanoRA’s Market Estimation report “Schizoaffective Disorder: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019–2025)” analyzed the current and upcoming opportunities in the Schizoaffective Disorder area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Schizoaffective Disorder industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Schizoaffective Disorder area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Schizoaffective Disorder Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Schizoaffective Disorder competitive environment. We have also prognosticated the Schizoaffective Disorder market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Epidemiology and Epidemiology forecast 2019 – 2025
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Estimated Pipeline Drug Approval Timelines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.”

  • “TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. EXECUTIVE SUMMARY
    2.1. MARKET SNAPSHOT, 2019-2025
    2.2. KEY EVENTS IN SCHIZOAFFECTIVE DISORDER MARKET, 2015-2030
    2.3. PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES
    2.4. KEY MAJOR FINDINGS
    2.4.1. DRIVERS
    2.4.2. RESTRAINTS
    2.4.1. UNMET NEEDS AND OPPORTUNITIES
    3. DISEASE OVERVIEW
    3.1. DISEASE DEFINITION & SYMPTOMS
    3.1.1. CLINICAL MANIFESTATIONS
    3.1.2. PATHOGENESIS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHM AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    3.6. EPIDEMIOLOGY FORECAST
    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4. MARKET OVERVIEW
    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    4.2. PRICING AND REIMBURSEMENT
    4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
    4.5. NEW DRUG APPROVALS (EMA) SINCE 2010
    4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    5.1.2. PHASE 3 MOLECULES
    5.1.3. PHASE 2 MOLECULES
    5.1.4. PHASE 1 MOLECULES
    5.1.5. PRECLINICAL MOLECULES
    5.1.6. EARLY R&D MOLECULES
    5.1.7. INACTIVE AND TERMINATED MOLECULES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6 PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES
    5.7. ESTIMATED APPROVAL TIMELINES
    5.7.1. METHODOLOGY
    5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    6. SCHIZOAFFECTIVE DISORDER CLINICAL TRIALS SUMMARY
    6.1. SCHIZOAFFECTIVE DISORDER PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
    6.1.1. KEY PHASE 3 RESULTS
    6.1.2. KEY PHASE 2 RESULTS
    6.2. ONGOING CLINICAL TRIALS SUMMARY
    6.2.1. KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    6.2.2. KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    6.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
    6.3 PLANNED CLINICAL TRIALS SUMMARY
    6.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    6.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
    6.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
    6.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
    7. SCHIZOAFFECTIVE DISORDER MARKET BY DRUG CLASS
    8. SCHIZOAFFECTIVE DISORDER MARKET BY ROUTE OF ADMINISTRATION
    9. SCHIZOAFFECTIVE DISORDER MARKET BY GEOGRAPHY
    9.1. UNITED STATES
    9.1.1. MARKET TRENDS AND GROWTH FACTORS
    9.1.2. UNMET NEEDS AND OPPORTUNITIES
    9.1.3. US SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.2. UNITED KINGDOM
    9.2.1. MARKET TRENDS AND GROWTH FACTORS
    9.2.2. UNMET NEEDS AND OPPORTUNITIES
    9.2.3. UK SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.3. GERMANY
    9.3.1. MARKET TRENDS AND GROWTH FACTORS
    9.3.2. GERMANY SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.4. FRANCE
    9.4.1. MARKET TRENDS AND GROWTH FACTORS
    9.4.2. UNMET NEEDS AND OPPORTUNITIES
    9.4.3. FRANCE SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.5. ITALY
    9.5.1. MARKET TRENDS AND GROWTH FACTORS
    9.5.2. UNMET NEEDS AND OPPORTUNITIES
    9.5.3. ITALY SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.6. SPAIN
    9.6.1. MARKET TRENDS AND GROWTH FACTORS
    9.6.2. UNMET NEEDS AND OPPORTUNITIES
    9.6.3. SPAIN SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.7. JAPAN
    9.7.1. MARKET TRENDS AND GROWTH FACTORS
    9.7.2. UNMET NEEDS AND OPPORTUNITIES
    9.7.3. JAPAN SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.8. CHINA
    9.8.1. MARKET TRENDS AND GROWTH FACTORS
    9.8.2. UNMET NEEDS AND OPPORTUNITIES
    9.8.3. CHINA SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.9. INDIA
    9.9.1. MARKET TRENDS AND GROWTH FACTORS
    9.9.2. UNMET NEEDS AND OPPORTUNITIES
    9.9.3. INDIA SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.10. BRAZIL
    9.10.1. MARKET TRENDS AND GROWTH FACTORS
    9.10.2. UNMET NEEDS AND OPPORTUNITIES
    9.10.3. BRAZIL SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.11. RUSSIA
    9.11.1. MARKET TRENDS AND GROWTH FACTORS
    9.11.2. UNMET NEEDS AND OPPORTUNITIES
    9.11.3. RUSSIA SCHIZOAFFECTIVE DISORDER MARKET SIZE (2018), FORECAST (2019-2025)
    9.12. ROW
    9.12.1. MARKET TRENDS AND GROWTH FACTORS
    9.12.2. UNMET NEEDS AND OPPORTUNITIES
    9.12.3. ROW MARKET SIZE (2018), FORECAST (2019-2025)
    10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    10.1. COMPANIES
    10.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
    10.1.2. TOP 20 EMERGING COMPANIES IN THE SCHIZOAFFECTIVE DISORDER AREA
    10.2. UNIVERSITIES AND INSTITUTES
    11. ABBREVIATIONS
    LIST OF TABLES:
    TABLE 1: REPORT HIGHLIGHTS IN NUMERICALS
    TABLE 2: LIST OF FDA APPROVED DRUGS FOR SCHIZOAFFECTIVE DISORDER
    TABLE 3: LIST OF EMA APPROVED DRUGS FOR SCHIZOAFFECTIVE DISORDER
    TABLE 4: SCHIZOAFFECTIVE DISORDER EPIDEMIOLOGY (2018), FORECAST (2019-2025)
    TABLE 5: MAJOR ACQUISITIONS AND MERGERS IN SCHIZOAFFECTIVE DISORDER AREA
    TABLE 6: MAJOR COLLABORATIVE AGREEMENTS IN SCHIZOAFFECTIVE DISORDER AREA
    TABLE 7: MAJOR LICENSING AGREEMENTS IN SCHIZOAFFECTIVE DISORDER AREA
    TABLE 8: MAJOR PARTNERSHIPS AND JOINT VENTURE IN SCHIZOAFFECTIVE DISORDER AREA
    TABLE 9: MAJOR GRANTS AND FUNDINGS IN SCHIZOAFFECTIVE DISORDER AREA
    TABLE 10: MAJOR ALLIANCE DEALS IN SCHIZOAFFECTIVE DISORDER AREA
    TABLE 11: US FDA APPROVED DRUGS FOR SCHIZOAFFECTIVE DISORDER SINCE 2010
    TABLE 12: EX-US APPROVED DRUGS FOR SCHIZOAFFECTIVE DISORDER SINCE 2010
    TABLE 13: PRE-REGISTRATION (FILED) MOLECULES IN THE SCHIZOAFFECTIVE DISORDER DRUG PIPELINE
    TABLE 14: PHASE 3 MOLECULES IN THE SCHIZOAFFECTIVE DISORDER DRUG PIPELINE
    TABLE 15: PHASE 2 MOLECULES IN THE SCHIZOAFFECTIVE DISORDER DRUG PIPELINE
    TABLE 16: PHASE 1 MOLECULES IN THE SCHIZOAFFECTIVE DISORDER DRUG PIPELINE
    TABLE 17: PRECLINICAL MOLECULES IN THE SCHIZOAFFECTIVE DISORDER DRUG PIPELINE
    TABLE 18: EARLY R&D MOLECULES IN THE SCHIZOAFFECTIVE DISORDER DRUG PIPELINE
    TABLE 19: TERMINATED AND INACTIVE MOLECULES IN THE SCHIZOAFFECTIVE DISORDER DRUG PIPELINE
    TABLE 20: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
    TABLE 21: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
    TABLE 22: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE MOLECULES BY UNIVERSITIES
    TABLE 23: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE MOLECULES BY INSTITUTES
    TABLE 24: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
    TABLE 25: KEY PHASE 3 ONGOING CLINICAL TRIALS
    TABLE 26: KEY PHASE 2 ONGOING CLINICAL TRIALS
    TABLE 27: KEY PHASE 1 ONGOING CLINICAL TRIALS
    TABLE 28: PLANNED CLINICAL TRIALS FOR THE SCHIZOAFFECTIVE DISORDER AREA
    TABLE 29: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
    TABLE 30: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
    TABLE 31: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
    TABLE 32: GLOBAL SCHIZOAFFECTIVE DISORDER MARKET BY DRUG CLASS (2019-2025)
    TABLE 33: GLOBAL SCHIZOAFFECTIVE DISORDER MARKET BY ROA (2019-2025)
    TABLE 34: STRENGTH, DOSAGE AND ROA OF SCHIZOAFFECTIVE DISORDER DRUGS
    TABLE 35: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF SCHIZOAFFECTIVE DISORDER PER YEAR
    TABLE 36: GLOBAL SCHIZOAFFECTIVE DISORDER MARKET BY GEOGRAPHY, MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 37: US MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 38: UK MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 39: GERMANY MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 40: FRANCE MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 41: ITALY MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 42: SPAIN MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 43: JAPAN MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 44: CHINA MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 45: INDIA MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 46: BRAZIL MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 47: RUSSIA MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 48: ROW MARKET SIZE (2018), FORECAST (2019-2025)
    TABLE 49: LIST OF ESTABLISHED COMPANIES IN THE SCHIZOAFFECTIVE DISORDER AREA
    TABLE 50: LIST OF EMERGING COMPANIES IN THE SCHIZOAFFECTIVE DISORDER AREA
    TABLE 51: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
    TABLE 52: COMPETITIVE OPPORTUNITIES, INSTITUTES
    (ABOVE MENTIONED TABLES ARE A FEW AMONG THE TOTAL 97 TABLES IN THE REPORT)
    LIST OF FIGURES:
    FIGURE 1: GLOBAL SCHIZOAFFECTIVE DISORDER MARKET 2019-2025: MARKET SNAPSHOT
    FIGURE 2: GLOBAL SCHIZOAFFECTIVE DISORDER MARKET BY GEOGRAPHY 2018 V/S 2025
    FIGURE 3: SCHIZOAFFECTIVE DISORDER MARKET BY ROA, 2018
    FIGURE 4: SCHIZOAFFECTIVE DISORDER MARKET BY AGE GROUP, 2018
    FIGURE 5: KEY INFLECTION POINTS IN SCHIZOAFFECTIVE DISORDER MARKET (2015-2030)
    FIGURE 6: SCHIZOAFFECTIVE DISORDER MAJOR FINDINGS
    FIGURE 7: MEDICAL EXPENDITURES FOR SCHIZOAFFECTIVE DISORDER
    FIGURE 8: SCHIZOAFFECTIVE DISORDER EPIDEMIOLOGY (2018), FORECAST (2019-2025)
    FIGURE 9: OVERALL DEALS ACTIVITY IN SCHIZOAFFECTIVE DISORDER AREA
    FIGURE 10: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
    FIGURE 11: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
    FIGURE 12: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 13: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
    FIGURE 14: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    FIGURE 15: SCHIZOAFFECTIVE DISORDER DRUG PIPELINE ANALYSIS BY DRUG CLASS
    FIGURE 16: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
    FIGURE 17: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
    FIGURE 18: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
    FIGURE 19: GRAPHICAL REPRESENTATION OF GLOBAL SCHIZOAFFECTIVE DISORDER MARKET BY DRUG CLASS
    FIGURE 20: GRAPHICAL REPRESENTATION OF GLOBAL SCHIZOAFFECTIVE DISORDER MARKET BY ROA
    FIGURE 21: GRAPHICAL REPRESENTATION, US MARKET SIZE 2018 V/S 2025
    FIGURE 22: GRAPHICAL REPRESENTATION, UK MARKET SIZE 2018 V/S 2025
    FIGURE 23: GRAPHICAL REPRESENTATION, GERMANY MARKET SIZE 2018 V/S 2025
    FIGURE 24: GRAPHICAL REPRESENTATION, FRANCE MARKET SIZE 2018 V/S 2025
    FIGURE 25: GRAPHICAL REPRESENTATION, ITALY MARKET SIZE 2018 V/S 2025
    FIGURE 26: GRAPHICAL REPRESENTATION, SPAIN MARKET SIZE 2018 V/S 2025
    FIGURE 27: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2018 V/S 2025
    FIGURE 28: GRAPHICAL REPRESENTATION, CHINA MARKET SIZE 2018 V/S 2025
    FIGURE 29: GRAPHICAL REPRESENTATION, INDIA MARKET SIZE 2018 V/S 2025
    FIGURE 30: GRAPHICAL REPRESENTATION, BRAZIL MARKET SIZE 2018 V/S 2025
    FIGURE 31: GRAPHICAL REPRESENTATION, RUSSIA MARKET SIZE 2018 V/S 2025
    FIGURE 32: GRAPHICAL REPRESENTATION, ROW MARKET SIZE 2018 V/S 2025
    FIGURE 33: COMPANY FINANCIAL INFORMATION
    FIGURE 34: COMPANY SWOT ANALYSIS
    (ABOVE MENTIONED FIGURES ARE A FEW AMONG THE TOTAL 51 FIGURES IN THE REPORT)”

Pricing

Individual Pricing $3500

Corporate Pricing $3500

Enterprise Pricing $3500

(We are offering all the above license types for a single price!!)